George Frangeskides, Exec-Chair at Alba Mineral Resources, discusses grades at the Clogau Gold Mine. Watch the full video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,708.60
Bid: 1,708.40
Ask: 1,708.80
Change: 3.40 (0.20%)
Spread: 0.40 (0.023%)
Open: 1,701.60
High: 1,713.00
Low: 1,699.40
Prev. Close: 1,705.20
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

EXTRA: GlaxoSmithKline Lifts Outlook, Partners On Genetic Profiling

Wed, 25th Jul 2018 13:54

LONDON (Alliance News) - GlaxoSmithKline said Wednesday it is taking new approach to research & development by partnering with genetic profiling company 23andMe Inc, as it reported a strong set of interim results.

GSK was the second best performer in London's FTSE 100 index on Wednesday with shares up 1.6% at 1,581.00 pence.

23andMe has more than 5 million customers who send genetic samples to the company which are then tested against its extensive genetic database. The samples are added to that database, increasing its accuracy.

GSK and 23andMe have signed an exclusive four-year collaboration agreement in which Glaxo will use 23andMe's extensive database to improve its understanding of diseases, determine which patients will respond best to treatments, and more effectively recruit and identify patients for clinical studies.

The collaboration agreement can be extended for a fifth year. If this occurs, GSK will then become an exclusive collaborator of 23andMe for drug targeting programmes.

Glaxo also intends to invest in machine learning and use computers to assess new assets. The company has said it will invest in gene editing technologies such as CRISPR.

Glaxo expects to launch two new dual therapy treatments, one for HIV and another to treat a type of bone marrow cancer, before the end of 2020. Past that point Glaxo said it "expects to launch multiple medicines from its promising, early-stage...portfolio."

The announcements came as Glaxo released its second quarter and first half results. For half-year ended June 30, the company's pretax profit was GBP1.72 billion, up 25% from GBP1.37 billion the year before.

The result was weighted toward the first quarter, with the second quarter contributing GBP614 million to profit. This was nonetheless an improved performance over the 2017 second quarter when it recorded a GBP178 million loss.

The company's revenue reduced in the first half to GBP14.53 billion from GBP14.70 billion. The company's second quarter contributed GBP7.31 billion to first half revenue.

Glaxo declared a 19 pence per share dividend for the second quarter and said that it continues to expect full dividend dividend to total 80p per share.

Moving forward, Glaxo upgraded its full-year expectations following the successful launch of its shingles vaccine Shingrix, as well as increased earnings from its recent buyout of Novartis International AG's stake in a joint venture.

The healthcare company expects 2018 adjusted earnings per share growth of between 7% and 10% at a constant exchange rate provided a generic competitor to the company's asthma drug Advair is not introduced in the US.

If a generic to Advair is introduced, then Glaxo expects annual adjusted earnings per share growth of between 4% and 7%.

"We are today upgrading our guidance for constant exchange rate growth in adjusted earnings per share for 2018. This reflects increased sales expectations for Shingrix, the positive effect of the completed consumer healthcare buyout as well as the delay of a potential generic version of Advair in the US...We remain increasingly confident in our ability to deliver mid to high single digit growth in adjusted earnings per share," Glaxo Chief Executive Emma Walmsley said.

Glaxo spent GBP925 million on research and development in the second quarter, bringing its half-year expenditure to GBP1.83 billion versus GBP2.22 billion the year prior.

The company announced a new restructuring programme which aims to deliver GBP400 million in annual cost savings by 2024. The restructuring is expected to cost GBP1.7 billion, comprised of a GBP800 million cash cost and a GBP900 million non-cash cost.

The savings made by the programme are intended to fund Glaxo's research & development costs.

In its most recent quarter, ended June 30, the company's vaccines business saw the most improvement, with turnover up 13% at an adjusted earnings rate to GBP1.25 billion. This was led by sales of GSK's shingles vaccine Shingrix in the US, alongside an increasing demand for hepatitis vaccines.

In both the US and Canada, Shingrix recorded sales of GBP167 million in the second quarter of 2018 and achieved a 98% market share. The company expects its Shingrix sales to be between GBP600 million and GBP650 million in 2018, which was a significant factor in GSK's move to upgrade its guidance for the year.

At an adjusted earnings rate, Glaxo's pharmaceutical sales dropped 3% to GBP4.23 billion and consumer healthcare sales declined by 1% to GBP1.83 billion. On an adjusted earnings basis, therefore, GSK's vaccines business was its only improver in terms of sales performance.

The US was also the company's only region to show improvement on that basis, with turnover up 2% at GBP2.79 billion while European and international sales declined.

More News
19 Mar 2024 09:21

LONDON BROKER RATINGS: Investec cuts ConvaTec; RBC raises Vistry

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning:

Read more
18 Mar 2024 12:00

GSK unveils promising results from endometrial cancer trial

(Sharecast News) - GSK unveiled promising outcomes from a phase three trial of 'Jemperli', or dostarlimab, in treating primary advanced or recurrent endometrial cancer on Monday.

Read more
18 Mar 2024 08:47

TOP NEWS: Pfizer launches GBP2 billion sale of 8% stake in Haleon

(Alliance News) - Haleon PLC on Monday said Pfizer Inc plans to sell around GBP2 billion in Haleon shares, some of which will be bought back by Haleon.

Read more
18 Mar 2024 08:47

GSK says Jemperli combination gets good results for endometrial cancer

(Alliance News) - GSK PLC on Monday said a test of its Jemperli drug in combination with chemotherapy has shown it reduced the risk of death in patients with endometrial cancer by nearly a third.

Read more
7 Mar 2024 09:38

GSK observes positive data in Blenrep trial for blood cancer treatment

(Alliance News) - GSK PLC on Thursday announced positive results for Blenrep for the treatment of multiple myeloma.

Read more
7 Mar 2024 07:21

GSK reports more encouraging trial results for Blenrep

(Sharecast News) - GSK unveiled encouraging results from its 'DREAMM-8' phase three trial on Thursday, comparing the efficacy of 'Blenrep', or belantamab mafodotin, in combination with pomalidomide plus dexamethasone, or PomDex, against the standard treatment of bortezomib plus PomDex in relapsed or refractory multiple myeloma patients.

Read more
5 Mar 2024 11:03

GSK says ViiV's cabotegravir study supports longer HIV dose interval

(Alliance News) - GSK PLC on Tuesday celebrated study results from ViiV Healthcare Ltd, that showed an investigational formulation of cabotegravir can be dosed at four-month intervals.

Read more
5 Mar 2024 07:26

GSK's ViiV upbeat on ultra-long-acting HIV treatment study

(Sharecast News) - GSK announced on Tuesday that its specialist GIV joint venture with Pfizer and Shionogi, ViiV Healthcare, had reported encouraging results from its phase one clinical trial of an investigational formulation of cabotegravir, termed cabotegravir ultra long-acting (CAB-ULA).

Read more
29 Feb 2024 09:44

TOP NEWS: GSK avoids "protracted litigation" with Zantac settlement

(Alliance News) - GSK PLC on Thursday emphasised its commitment to science, as it reached another settlement in ongoing litigation over alleged links between its heartburn drug and cancer.

Read more
29 Feb 2024 07:22

GSK reaches settlement in another Zantac case

(Sharecast News) - GSK announced a confidential settlement with Boyd/Steenvoord, effectively resolving a case filed in California state court over its discontinued heartburn drug Zantac.

Read more
26 Feb 2024 08:25

GSK gonorrhoea treatment achieves efficacy endpoint in latest trial

(Alliance News) - GSK PLC on Monday announced positive results from the latest trial of its oral gonorrhoea treatment, showing it to be on par with intramuscular therapies.

Read more
26 Feb 2024 07:22

GSK reports positive results from gonorrhoea treatment trial

(Sharecast News) - GSK announced encouraging headline outcomes from its trial of gepotidacin, an oral antibiotic aiming to address uncomplicated urogenital gonorrhoea in adolescents and adults, on Monday.

Read more
21 Feb 2024 09:47

GSK reports encouraging results for ViiV's Cabenuva HIV treatment

(Alliance News) - GSK PLC on Wednesday said that its majority-owned company ViiV Healthcare had received positive interim data from ongoing trials of its injectable HIV treatment.

Read more
21 Feb 2024 07:22

GSK's ViiV sees success in latest HIV treatment trial

(Sharecast News) - GSK's specialist HIV unit ViiV Healthcare, which it owns in partnership with Pfizer and Shionogi, unveiled promising findings from the 'LATITUDE' phase three trial of its long-acting injectable HIV treatment Cabenuva on Wednesday.

Read more
20 Feb 2024 15:10

PRESS: AJ Bell founder to join Applied Nutrition ahead of IPO - Sky

(Alliance News) - Supplements maker Applied Nutrition, plotting a London stock market float, is to add AJ Bell PLC founder Andy Bell as its chair, Sky News reported on Tuesday.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.